1.Amsterdam, JD. Monoamine oxidase inhibitor therapy in severe and resistant depression. Psychiatr Ann. 2006;36:607–613.Google Scholar

2.Stahl, SM. Stahl's Essential Psychopharmacology. 3rd ed. New York, NY: Cambridge University Press; 2008.Google Scholar

3.Zisook, S. A clinical overview of monoamine oxidase inhibitors. Psychosomatics. 1985;26:240-246, 251.Google Scholar

4.Krishnan, KR. Revisiting monoamine oxidase inhibitors. J Clin Psychiatry. 2007;68(suppl 8):35–41.Google Scholar

5.Tollefson, GD. Monoamine oxidase inhibitors: a review. J Clin Psychiatry. 1983;44:280–288.Google Scholar

6.Versiani, M, Nardi, AE, Mundim, FD, et al.The long-term treatment of social phobia with moclobemide. Int Clin Psychopharmacol. 1996;11 (suppl 3):83–88.CrossRefGoogle ScholarPubMed

7.Cole, JO, Bodkin, JA. MAO inhibitors: an option worth trying in treatment-resistant cases. Current Psychiatry. 2002;1:40–47.Google Scholar

8.Rascol, O. Rasagiline in the pharmacotherapy of Parkinson's disease—a review. Expert Opin Pharmacother. 2005;6:2061–2075.Google Scholar

9.Cascade, EF, Kalali, AH, Preskom, SH. Emsam: The first year. Psychiatry. 2007:19–21.Google Scholar

10.Stahl, SM. Essential Psychopharmacology: The Prescribers Guide. New York, NY: Cambridge University Press; 2006.Google Scholar

11.Schatzberg, AF. Safety and tolerability of antidepressants: weighing the impact on treatment decisions. J Clin Psychiatry. 2007;68(suppl 8):26–34.Google Scholar

12.Jacob, CP, Muller, J, Schmidt, M, et al.Cluster B personality disorders are associated with allelic variation of monoamine oxidase A activity. Neuropsychopharmacoloy. 2005;30:1711–1718.Google Scholar

13.Ballas, CA, Evans, DL, Dinges, DF. Psychostimulants in psychiatry: amphetamine, methylphenidate and modafinil. In: Textbook of Psychopharmacology. Schatzberg, A, Nemeroff, C, eds. Washington, DC: American Psychiatric Publishing, Inc.; 2004:671–684.Google Scholar

14.Kupiec, TC, Chaturvedi, AK. Stereochemical determination of selegiline metabolites in postmortem biological specimens. J Forensic Sci. 1999;44:222–226.Google Scholar

15.Shin, H. Metabolism of selegiline in humans: identification, excretion, and stereochemistry of urine metabolites. Drug Metab Dispos. 1997;25:657–662.Google Scholar

16.Magyar, MK, Szatmary, I, Szebeni, G, Lengyel, J. Pharmacokinetic studies of (-)-deprenyl and some of its metabolites in mouse. J Neural Transm Suppl. 2007;72:165–173.Google Scholar

17.Feinberg, SS. Combining stimulants with monoamine oxidase inhibitors: a review of uses and one possible additional indication. J Clin Psychiatry. 2004;65:1520–1524.Google Scholar

18.Feighner, JP, Herbstein, J, Damlouji, N. Combined MAOI, TCA and direct stimulant therapy of treatment-resistant depression. J Clin Psychiatry. 1985;46:206–209.Google Scholar

19.Fawcett, J, Kravitz, HM, Zajecka, JM, Schaff, MR. CNS stimulant potentiation of monoamine oxidase inhibitors in treatment-refractory depression. J Clin Psychopharmacol. 1991;11:127–132.CrossRefGoogle ScholarPubMed

20.Schoepp, DD, Azzarro, AJ. Specificity of endogenous substrates for types A and B monoamine oxidase in rat striatum. J Neurochem. 1981;36:2025–2031.Google Scholar

21.Fowler, CJ, Tipton, KF. On the substrate specificities of the two forms of monoamine oxidase. J Pharm Pharmacol. 1984;36:111–115.Google Scholar

22.Chen, K, Holschneider, DP, Wu, W, Rebrin, I, Shih, JC. A spontaneous point mutation produces monoamine oxidase A/B knock-out mice with greatly elevated monoamines and anxiety-like behavior. Biol Chem. 2004;279:39645–39652.Google Scholar

23.Da Prada, M, Kettler, R, Keller, HH, Burkard, WP, Muggli-Maniglio, D, Haefely, WE. Neurochemical profile of moclobemide, a short-acting and reversible inhibitor of monoamine oxidase type A. Pharmacol Exp Ther. 1989;248:400–414.Google Scholar

24.Lotufo-Neto, F, Trivedi, M, Thase, ME. Meta-analysis of the reversible inhibitors of monoamine oxidase type A moclobemide and brofaromine for the treatment of depression. Neuropsychopharmacology. 1999;20:226–247.Google Scholar

25.Patkar, AA, Pae, CU, Masand, PS. Transdermal selegiline: the new generation of monoamine oxidase inhibitors. CNS Spectr. 2006;11:363–373.Google Scholar

26.Mendis, N, Pare, CM, Sandier, M, Glover, V, Stern, GM. Is the failure of (-) deprenyl, a selective monoamine oxidase B inhibitor, to alleviate depression related to freedom from the cheese effect? Psychopharmacology. 1981;73:87–90.Google Scholar

27.Mann, JJ, Frances, A, Kaplan, RD, Kocsis, J, Peselow, ED, Gershon, S. The relative efficacy of I-deprenyl, a selective monoamine oxidase type B inhibitor, in endogenous and nonendogenous depression. J Clin Psychopharmacol. 1982;2:54–57.Google Scholar

28.Sunderland, T, Cohen, RM, Molchan, S, et al.High-dose selegiline in treatment resistant older depressive patients. Arch Gen Psychiatry. 1994;51:607–615.Google Scholar

29.Birkmeyer, W. Implications of combined treatment with “Madopar” and L-deprenyl in Parkinson's disease: a long-term study. Lancet. 1977;26:439–443.Google Scholar

30.Postma, JU, Vranesic, D. Moclobemide in the treatment of depression in demented geriatric patients. Acta Ther. 1985;11:249–252.Google Scholar

31.Nutt, D, Demyttenaere, K, Janka, Z, et al.The other face of depression, reduced positive affect: The role of catecholamines in causation and cure. Psychopharmacol. 2007;21:461–471.Google Scholar

32.McCabe, B, Tsuang, MT. Dietary consideration in MAO inhibitor regimens. J Clin Psychiatry. 1982;43:178–181.Google ScholarPubMed

33.Gardner, DM, Shulman, KI, Walker, SE, Tailor, SA. The making of a user friendly MAOI diet. J Clin Psychiatry. 1996;57:99–104.Google Scholar

34.Da Prada, M, Zurcher, G, Wuthrich, I, Haefely, WE. On tyramine, food, beverages and the reversible MAO inhibitor moclobemide. J Neural Transm Suppl. 1988;26:31–56.Google Scholar

35.Sweet, RA, Brown, EJ, Heimberg, RG, et al.Monoamine oxidase inhibitor dietary restrictions: what are we asking patients to give up? J Clin Psychiatry. 1995;56:196–201.Google Scholar

36.Shulman, KI, Walker, SE, MacKenzie, S, Knowles, S. Dietary restriction, tyramine, and the use of monoamine oxidase inhibitors. J Clin Psychopharmacol. 1989;9:397–402.Google Scholar

37.Shulman, KI, Walker, SE. Refining the MAOI diet: tyramine content of pizzas and soy products. J Clin Psychiatry. 1999;60:191–193.Google Scholar

38.Shulman, KI, Walker, SE. Psychiatr Ann. 2001;31:378–384.Google Scholar

39.Knoll, J, Magyar, K. Some puzzling pharmacological effects of monoamine oxidase inhibitors. Adv Biochem Psychopharmacol. 1972;5:393–408.Google Scholar

40.Wecker, L, Copeland, JS, Pacheco, MA. Transdermal selegiline: targeted effects on monoamine oxidases in the brain. Biol Psychiatry. 2003:541099–541104.Google Scholar

41.Mawhinney, M, Cole, D, Azzaro, AJ. Daily transdermal administration of selegiline to guinea-pigs preferentially inhibits monoamine oxidase activity in brain when compared with intestinal and hepatic tissues. J Pharm Pharmacol. 2003;55:27–34.Google Scholar

42.Keller, HH, Kettler, R, Burkard, WP, et al. Preclinical characteristics of moclobemide, a short-acting MAO-A inhibitor with low liability to enhance the tyramine pressor effect. Abstract presented at: annual meeting of the Collegium Internationale Neuro-Psychopharmacologicum. Session 3102: Antidepressants and MAO inhibitors. August 16, 1988; Munich, GermanyGoogle Scholar

43.Priest, RG. Recent clinical development with reversible and selective amine oxidase inhibitors: a valuable addition to the armamentarium. J Clin Psychopharmacol. 1995, 15(suppl 2):1–3.Google Scholar

44.Stabl, M, Biziere, K, Schmid-Burgk, W, Amrein, R. Moclobemide vs tricyclic antidepressants and vs placebo in depressive states. J Neural Transm Suppl. 1989;28:77–89.Google Scholar

45.Angst, J, Amrein, R, Stabl, M. Moclobemide and tricyclic antidepressants in severe depression: meta-analysis and prospective studies. J Clin Psychopharmacol. 1995;15(4 suppl 2):16S–23S.Google Scholar

46.Amsterdam, JD. A double-blind, placebo-controlled trial of the safety and efficacy of selegiline transdermal system without dietary restrictions in patients with major depressive disorder. J Clin Psychiatry. 2003;64:208–214.Google Scholar

47.Robinson, DS. Transdermal selegiline: A new-generation MAOI. Primary Psychiatry. 2006;13:33–35.Google Scholar

48.Zsilia, G, Foldi, P, Held, G, Szekely, AM, Knoll, J. The effect of repeated doses of (-) deprenyl on the dynamics of monoaminergic transmission: comparison with clorgyline. Pol J Pharmacol Pharm. 1986;38:57–67.Google Scholar

49.Bodkin, JA, Siris, SG, Bermanzohn, PC, Hennen, J, Cole, JO. Double-blind, placebo-controlled, multicenter trial of selegiline augmentation of antipsychotic medication to treat negative symptoms in outpatients with schizophrenia. Am J Psychiatry. 2005;162:388–390.Google Scholar

50.Shimazu, S, Minami, A, Kusumoto, H, Yoneda, F. Antidepressant-like effects of selegiline in the forced swim test. Eur Neuropsychopharmacol. 2005;15:563–571.Google Scholar

51.Feiger, AD, Rickels, K, Rynn, MA, Zimbroff, DL, Robinson, DS. Selegiline transdermal system for the treatment of major depressive disorder: an 8-week, double-blind, placebo-controlled, flexible-dose titration trial. J Clin Psychiatry. 2006;67:1354–1361.Google Scholar

52.Blob, LF, Sharoky, M, Campbell, BJ, et al.Effects of a tyramine-enriched meal on blood pressure response in healthy male volunteers treated with selegiline transdermal system 6 mg/24 hour. CNS Spectr. 2007;12:25–34.Google Scholar

53.Sternbach, H. Serotonin syndrome: how to avoid, identify, and treat dangerous drug interactions. Current Psychiatry. 2003;2:15–23.Google Scholar

54.Gillman, PK. A review of serotonin toxicity data: implications for the mechanisms of antidepressant drug action. Biol Psychiatry. 2006;59:1046–1051.Google Scholar

55.Lawrence, KR, Adra, M, Gillman, PK. Serotonin toxicity associated with the use of linezolid: a review of postmarketing data. Clin Infect Dis. 2006;42:1578–1583.Google Scholar

56.Gillman, PK. Understanding toxidromes: serotonin toxicity. J Clin Psychopharmacol. 2005;25:625–626.Google Scholar

57.Ginsberg, DL. Psychopharmacology Reviews: serotonin syndrome due to interaction between antibiotic linezolidand norfluoxetine. Primary Psychiatry. 2005;12:27–28.Google Scholar

58.Berlanga, C, Ortega-Soto, HA. A 3-year follow-up of a group of treatment-resistant depressed patients with a MAOI/tricyclic combination. J Affect Disord. 1995;34:187–192.Google Scholar

59.Houtsmuller, EJ, Notes, LD, Newton, T, et al.Transdermal selegiline and intravenous cocaine: safety and interactions. Psychopharmacology. 2004;172:31–40.Google Scholar

60.Gillman, PK. Extracting value from case reports: lessons from serotonin toxicity. Anaesthesia. 2006;61:419–422.Google Scholar

61.Dvir, Y, Smallwood, P. Serotonin syndrome: a complex but easily avoidable condition. Gen Hosp Psychiatry. 2008;30:284–287.Google Scholar

62.Boyer, EW, Shannon, M. The serotonin syndrome. N Engl J Med. 2005;352:1112–1120.Google Scholar

63.Gillman, PK. Tricyclic antidepressant pharmacology and therapeutic drug interactions updated. Br J Pharmacol. 2007;151:737–748.Google Scholar

64.Sabelli, HC. Rapid treatment of depression with selegiline-phenylalanine combination. J Clin Psychiatry. 1991;52:137.Google Scholar

65.Taylor, BP, Quitkin, FM, McGrath, PJ, Stewart, JW. Do antihypertensives make tranylcypromine safer? Three case reports. J Clin Psychiatry. 2005;66:657–658.Google Scholar

66.Gillman, PK. Monoamine oxidase inhibitors, opioid analgesics and serotonin toxicity. Br J Anaesth. 2005;95:434–441.Google Scholar

67.Joffe, RT, Bakish, D. Combined SSRI-moclobemide treatment of psychiatric illness. J Clin Psychiatry. 1994;55:24–25.Google Scholar

68.Fuller, RW, Snoddy, HD. Inhibition of serotonin uptake and the toxic interaction between meperidine and monoamine oxidase inhibitors. Toxicol Appl Pharmacol. 1975;32:129–134.Google Scholar